MRIGlobal

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1943

Legal Domicile

Phone

8167537600

Tax Period

2024-10-01 to 2025-09-30

MRIGlobal, founded in 1943, is a major nonprofit in the Science & Technology sector that reported $115.8M in total revenue in fiscal year 2024.

Mission

To improve the lives of people through innovative scientific and engineering research.

Program Service Accomplishments

Program 1

Expenses: $36,380,350 Revenue: $10,893,593

Integrated Health Surveillance and Diagnostics - MRIGlobal performs research to counter threats to human health. In our world-class laboratories, our team supports all phases of immuno and molecular assays in our CAP/CLIA certified labs. Our capabilities range from the development of cutting-edge molecular and immunological assays focused on emerging highly infectious diseases, researching vaccines and therapeutics, and the advancement of novel, highly sensitive diagnostic assays, ushering them all through regulatory clearance.

Program 2

Expenses: $42,062,523 Revenue: $1,205,221

Integrated Defense Solutions - MRIGlobal guards human health and safety by defending against chemical, biological, and explosive threats. With decades of chemical warfare agent detection, evaluation, and assessment, our unique expertise and history combines scientific and engineering experts with state-of-the-art laboratory facilities to advance programs across the United States government and private sectors. This includes the design, building, testing, and evaluation of advanced products and technologies such as miniature devices capable of detecting toxic materials and chemical agents, field-deployable laboratories, and medical response systems that improve national defense and global health.

Program 3

Expenses: $16,993,626 Revenue: $8,244,642

Integrated Pharmaceutical Solutions - MRIGlobal bridges the gap between drug discovery and commercialization. We provide the necessary services including development, manufacturing, testing, and...

Integrated Pharmaceutical Solutions - MRIGlobal bridges the gap between drug discovery and commercialization. We provide the necessary services including development, manufacturing, testing, and clinical trial material management support for drug substances, drug products, intermediates, and impurities, including reference standard materials. Our team works in the appropriate regulatory framework, such as GLP, GMP, and in accordance with ICH guidelines to ensure strict compliance to quality and regulatory requirements. This work helps support informed public health decisions, and guiding investigational new drugs through development, clinical trials, and regulatory approvals.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $87,513,057

Program Service Revenue $26,075,073

Investment Income $2,155,629

Other Revenue $105,990

TOTAL REVENUE $115,849,749

Expense Breakdown

Grants Paid $25,000

Salaries & Benefits $55,860,018

Fundraising Expenses $0

Program Expenses $95,436,499

Other Expenses $65,913,444

TOTAL EXPENSES $121,798,462

Year-over-Year Comparison

	2024	2023	Change
Revenue	$115,849,749	$117,952,952	0.0%
Expenses	$121,798,462	$115,298,058	+0.1%
Net Income	$-5,948,713	$2,654,894	-3.2%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✓ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

497

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$2,876,568

Total Directors

$1,634,024

Key Employees

$830,258

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Ian M Colrain PhD	President and CEO	40.0	Officer Director	$943,691	$85,333	$1,029,024
Alexander G Garza MD MPH	Director	1.0	Director	$40,000	$0	$40,000
Amy Nachtigal	Director	1.0	Director	$47,500	$0	$47,500
Dan E Arvizu PhD	Director	1.0	Director	$40,000	$0	$40,000
David E Hall	Director	1.0	Director	$47,500	$0	$47,500
Douglas A Girod MD	Director	1.0	Director	$40,000	$0	$40,000
Heather Leith	Director	1.0	Director	$40,000	$0	$40,000
Josh Carpenter DPhil	Director	1.0	Director	$0	$0	$0
Julia M Wilson	Director	1.0	Director	$40,000	$0	$40,000
Laura Wright	Director	1.0	Director	$40,000	$0	$40,000
Neal Sharma	Director	1.0	Director	$40,000	$0	$40,000
Pamela R Berneking	Director	1.0	Director	$55,000	$0	$55,000
Scott M Smith PE	Director	1.0	Director	$47,500	$0	$47,500
Steffanie B Easter	Director	1.0	Director	$40,000	$0	$40,000
Wendy M Masiello	Director	1.0	Director	$40,000	$0	$40,000
William A Jeffrey PhD	Director	1.0	Director	$47,500	$0	$47,500
Amy M Bog PhD	Chief Innovation Officer	40.0	Officer	$400,380	$33,509	$433,889
Jessica J Zolynas	Chief Legal Officer & Corp Secretary	40.0	Officer	$364,629	$35,768	$400,397
Luke J McGlynn	Chief People Officer	40.0	Officer	$370,224	$61,792	$432,016
Martin J Nevshemal	CFO and Treasurer - Outgoing	40.0	Officer	$509,061	$72,181	$581,242
Stephanie DeFino	CFO and Treasurer	40.0	Officer	$0	$0	$0
Jason E Gordon	Senior Director	40.0	Key Emp	$209,916	$38,529	$248,445
Jonathan M White	Senior Director	40.0	Key Emp	$220,131	$48,344	$268,475
Kristine K Werking	Senior Director	40.0	Key Emp	$264,020	$49,318	$313,338
Dominie Garcia PhD	VP-Commercial Business Development	40.0	Highest	$353,318	$35,938	$389,256
Jerem G Swenddal	VP-Business Ops & Strategy	40.0	Highest	$275,198	$22,590	$297,788
Joseph A Bogan Jr PhD	Chief Research Fellow	40.0	Highest	$343,045	$28,029	$371,074
Michelle Rodrigues	VP-Government Business Development	40.0	Highest	$300,450	$31,829	$332,279
Richard A Winegar	Distinguished Research Fellow	40.0	Highest	$286,722	$31,815	$318,537
Carol F Blevins	Assistant Director	40.0		$194,109	$36,128	$230,237
Christopher W Hollars	Principal Advisor	40.0		$234,275	$40,044	$274,319

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$115,849,749	$121,798,462	$140,070,332	$-5,948,713
2024	$117,952,952	$115,298,058	$147,828,702	$2,654,894
2023	$119,632,626	$112,859,972	$148,628,423	$6,772,654
2023	No data	No data	No data	No data
2022	$128,594,894	$121,200,941	$137,683,275	$7,393,953
2021	$116,109,484	$107,631,775	$133,438,499	$8,477,709
2020	$102,654,783	$95,114,232	$116,923,133	$7,540,551
2019	$108,959,622	$103,621,879	$102,952,763	$5,337,743
2018	$109,624,647	$105,149,771	$93,326,926	$4,474,876